Lerner's UV light therapy for psoriasis gets FDA clearance
This article was originally published in Clinica
Executive Summary
Lerner Medical Devices' Levia, an at-home light therapy device, has received US FDA 510(k) clearance for the treatment of psoriasis. The product uses ultraviolet B (UVB) light to slow the growth of affected skin cells, and is designed to treat psoriasis of the scalp and small flare-ups of the disease. It can also be used in other skin conditions such as vitiligo, which causes depigmentation of patches of skin. The Levia system has delivery attachments, the Lite-Brush and Lite-Spot, which direct the UVB light to affected areas and minimise exposure of healthy skin. Lerner (Los Angeles, California) plans to launch the product this quarter.